EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient

Soomin Park iD, Seong-Jin Jo

The Journal of Dermatology · 2026-08 · 53 (8)

DOI: 10.1111/1346-8138.70335 ↗

Kurz gefasst

Leserbrief in der Zeitschrift The Journal of Dermatology, online erschienen am 01.06.2026. Verfasst von Soomin Park und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Seoul National University College of Medicine, and Seoul National University Hospital, Seoul, Korea. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paradoxical eczema (PE) is an increasingly recognized adverse effect of targeted psoriasis therapies, reported with biologics targeting tumor necrosis factor (TNF), interleukin (IL)- 17, IL-12/23, and IL-23 [1]. We describe a patient with chronic plaque psoriasis who developed PE sequentially with an IL-23 inhibitor (risankizumab), an IL-17 inhibitor (secukinumab), and a tyrosine kinase 2 (TYK2) inhibitor (deucravacitinib). A 58- year-old man with a 20-year history of psoriasis had previously received acitretin, methotrexate, cyclosporine, and phototherapy with inadequate disease control (Psoriasis Area and Severity Index (PASI) 17.5; body surface area (BSA) 15%). Risankizumab was initiated according to the standard schedule. By month 4, psoriasis had improved, but new facial pruritus with scaling developed. By month 7, psoriasis was almost completely controlled (PASI 0.5, BSA 1%), whereas pruritic eruptions had spread over the trunk and extremities. After 1 year, exudative

Schlagwörter

Stichwörter der Autor:innen

deucravacitinibeczemaparadoxical eczemapsoriasis

Autor:innen und Institutionen

  • Department of Dermatology, Seoul National University College of Medicine, and Seoul National University Hospital, Seoul, Korea.

ORCID-Profile: Soomin Park

Zitieren

APA

Park, S., & Jo, S. J. (2026). Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient. The Journal of Dermatology, 53(8). https://doi.org/10.1111/1346-8138.70335

Vancouver

Park S, Jo SJ. Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient. The Journal of Dermatology. 2026;53(8). doi:10.1111/1346-8138.70335

BibTeX
@article{Park2026,
  author = {Park, Soomin and Jo, Seong-Jin},
  title = {Sequential Paradoxical Eczema Following Interleukin‐23, Interleukin‐17, and Tyrosine Kinase 2 Inhibitors in a Single Psoriasis Patient},
  journal = {The Journal of Dermatology},
  year = {2026},
  volume = {53},
  number = {8},
  doi = {10.1111/1346-8138.70335}
}
Kostenlos starten →